NovaBridge Biosciences
0VY
Company Profile
Business description
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,813.10 | 55.80 | 0.64% |
| CAC 40 | 8,199.29 | 18.95 | -0.23% |
| DAX 40 | 24,616.22 | 142.83 | -0.58% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,373.20 | 5.15 | 0.05% |
| HKSE | 24,556.54 | 100.52 | -0.41% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 64,654.22 | 629.62 | 0.98% |
| NZX 50 Index | 13,095.64 | 57.40 | 0.44% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,592.70 | 59.20 | 0.69% |
| SSE Composite Index | 3,970.34 | 11.00 | 0.28% |